FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308294057> ?p ?o ?g. }

• W4308294057 endingPage "132.e5" @default.
• W4308294057 startingPage "132.e1" @default.
• W4308294057 abstract "Epstein-Barr virus (EBV) reactivation and EBV-related post-transplantation lymphoproliferative disorder (PTLD) are often fatal complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The risk of EBV reactivation may be mitigated by depletion of B cells with rituximab. Starting in January 2020, allo-HSCT recipients undergoing T-cell depletion with alemtuzumab received 1 dose of rituximab before transplantation. The objective of this study was to evaluate the cumulative incidence of EBV reactivation and EBV-PTLD in recipients of allo-HSCT and in vivo T-cell depletion with alemtuzumab who received pre-HSCT rituximab compared to patients who did not. This was a single-center retrospective analysis of adult patients who consecutively received an HLA-identical allo-HSCT between January 2019 and May 2021 and in vivo T-cell depletion with alemtuzumab. Patients were included in the rituximab cohort if they received rituximab within 6 months before their transplantation. The primary endpoint was incidence of EBV reactivation at day 180 among those receiving pre-HSCT rituximab versus those not receiving rituximab. Secondary endpoints included cumulative incidence of EBV-PTLD at 1 year, time to engraftment, immune reconstitution, and incidence of infections and acute graft-versus-host disease (aGVHD) at day 180. Eighty-six consecutive patients who received an allo-HSCT with alemtuzumab T-cell depletion were reviewed; 43 patients who received pre-HSCT rituximab after our protocol modification were compared to 43 patients who did not receive pre-HSCT rituximab before this change. Median age was 57 (interquartile range [IQR] 40-69) years, and the majority of patients had acute myeloid leukemia or myelodysplastic syndrome. Baseline characteristics were similar between the cohorts. EBV reactivation at day 180 occurred in 23 (53%) patients without prior rituximab exposure versus 0 patients with pre-HSCT rituximab exposure (P < .0001). Similarly, 6 patients without prior rituximab exposure developed PTLD at 1 year compared to no cases of PTLD among patients receiving pre-HSCT rituximab. There was no difference in neutrophil engraftment, incidence of infections, or aGVHD at day 180 between the 2 cohorts. There was a delay in time to platelet engraftment in the rituximab cohort (median 16 [IQR 15-20] days versus 15 [IQR 14-17] days; P = .04). Administration of pre-HSCT rituximab before allo-HSCT in patients receiving T-cell depletion with alemtuzumab was associated with a significant decrease in the risk for EBV reactivation and EBV-PTLD, without increasing aGVHD or infection rates." @default.
• W4308294057 created "2022-11-10" @default.
• W4308294057 creator A5001141136 @default.
• W4308294057 creator A5015249098 @default.
• W4308294057 creator A5015940536 @default.
• W4308294057 creator A5020403572 @default.
• W4308294057 creator A5026273223 @default.
• W4308294057 creator A5029912346 @default.
• W4308294057 creator A5030521849 @default.
• W4308294057 creator A5044134864 @default.
• W4308294057 creator A5044147163 @default.
• W4308294057 creator A5049384875 @default.
• W4308294057 creator A5049993701 @default.
• W4308294057 creator A5052662934 @default.
• W4308294057 creator A5055497641 @default.
• W4308294057 creator A5071121646 @default.
• W4308294057 creator A5071986683 @default.
• W4308294057 creator A5086433558 @default.
• W4308294057 creator A5089841936 @default.
• W4308294057 date "2023-02-01" @default.
• W4308294057 modified "2023-10-12" @default.
• W4308294057 title "Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients" @default.
• W4308294057 cites W1978468922 @default.
• W4308294057 cites W1983189402 @default.
• W4308294057 cites W1993516387 @default.
• W4308294057 cites W2008513538 @default.
• W4308294057 cites W2054279695 @default.
• W4308294057 cites W2403132235 @default.
• W4308294057 cites W2602198097 @default.
• W4308294057 cites W2914550450 @default.
• W4308294057 cites W3138843057 @default.
• W4308294057 cites W3191673266 @default.
• W4308294057 cites W4283073746 @default.
• W4308294057 doi "https://doi.org/10.1016/j.jtct.2022.10.023" @default.
• W4308294057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36334653" @default.
• W4308294057 hasPublicationYear "2023" @default.
• W4308294057 type Work @default.
• W4308294057 citedByCount "2" @default.
• W4308294057 countsByYear W43082940572023 @default.
• W4308294057 crossrefType "journal-article" @default.
• W4308294057 hasAuthorship W4308294057A5001141136 @default.
• W4308294057 hasAuthorship W4308294057A5015249098 @default.
• W4308294057 hasAuthorship W4308294057A5015940536 @default.
• W4308294057 hasAuthorship W4308294057A5020403572 @default.
• W4308294057 hasAuthorship W4308294057A5026273223 @default.
• W4308294057 hasAuthorship W4308294057A5029912346 @default.
• W4308294057 hasAuthorship W4308294057A5030521849 @default.
• W4308294057 hasAuthorship W4308294057A5044134864 @default.
• W4308294057 hasAuthorship W4308294057A5044147163 @default.
• W4308294057 hasAuthorship W4308294057A5049384875 @default.
• W4308294057 hasAuthorship W4308294057A5049993701 @default.
• W4308294057 hasAuthorship W4308294057A5052662934 @default.
• W4308294057 hasAuthorship W4308294057A5055497641 @default.
• W4308294057 hasAuthorship W4308294057A5071121646 @default.
• W4308294057 hasAuthorship W4308294057A5071986683 @default.
• W4308294057 hasAuthorship W4308294057A5086433558 @default.
• W4308294057 hasAuthorship W4308294057A5089841936 @default.
• W4308294057 hasConcept C119060515 @default.
• W4308294057 hasConcept C126322002 @default.
• W4308294057 hasConcept C203014093 @default.
• W4308294057 hasConcept C2776995267 @default.
• W4308294057 hasConcept C2777408962 @default.
• W4308294057 hasConcept C2779015954 @default.
• W4308294057 hasConcept C2779338263 @default.
• W4308294057 hasConcept C2780653079 @default.
• W4308294057 hasConcept C2781146716 @default.
• W4308294057 hasConcept C2911091166 @default.
• W4308294057 hasConcept C71924100 @default.
• W4308294057 hasConcept C88879693 @default.
• W4308294057 hasConcept C90924648 @default.
• W4308294057 hasConceptScore W4308294057C119060515 @default.
• W4308294057 hasConceptScore W4308294057C126322002 @default.
• W4308294057 hasConceptScore W4308294057C203014093 @default.
• W4308294057 hasConceptScore W4308294057C2776995267 @default.
• W4308294057 hasConceptScore W4308294057C2777408962 @default.
• W4308294057 hasConceptScore W4308294057C2779015954 @default.
• W4308294057 hasConceptScore W4308294057C2779338263 @default.
• W4308294057 hasConceptScore W4308294057C2780653079 @default.
• W4308294057 hasConceptScore W4308294057C2781146716 @default.
• W4308294057 hasConceptScore W4308294057C2911091166 @default.
• W4308294057 hasConceptScore W4308294057C71924100 @default.
• W4308294057 hasConceptScore W4308294057C88879693 @default.
• W4308294057 hasConceptScore W4308294057C90924648 @default.
• W4308294057 hasIssue "2" @default.
• W4308294057 hasLocation W43082940571 @default.
• W4308294057 hasLocation W43082940572 @default.
• W4308294057 hasOpenAccess W4308294057 @default.
• W4308294057 hasPrimaryLocation W43082940571 @default.
• W4308294057 hasRelatedWork W1977557500 @default.
• W4308294057 hasRelatedWork W1983898630 @default.
• W4308294057 hasRelatedWork W2014666768 @default.
• W4308294057 hasRelatedWork W2065956150 @default.
• W4308294057 hasRelatedWork W2072345784 @default.
• W4308294057 hasRelatedWork W2084366804 @default.
• W4308294057 hasRelatedWork W2122961952 @default.
• W4308294057 hasRelatedWork W2167253177 @default.
• W4308294057 hasRelatedWork W2275283081 @default.
• W4308294057 hasRelatedWork W4254459495 @default.

• next